Selected article for: "lopinavir ritonavir and lpv rtv lopinavir ritonavir"
Author: Nukoolkarn, Veena; Lee, Vannajan Sanghiran; Malaisree, Maturos; Aruksakulwong, Ornjira; Hannongbua, Supot
Title: Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CL(pro) inhibitors
  • Cord-id: r49ox9x9
  • Document date: 2008_10_21
    • ID: r49ox9x9
    Snippet: Since the emergence of the severe acute respiratory syndrome (SARS) to date, neither an effective antiviral drug nor a vaccine against SARS is available. However, it was found that a mixture of two HIV-1 proteinase inhibitors, lopinavir and ritonavir, exhibited some signs of effectiveness against the SARS virus. To understand the fine details of the molecular interactions between these proteinase inhibitors and the SARS virus via complexation, molecular dynamics simulations were carried out for
    Document: Since the emergence of the severe acute respiratory syndrome (SARS) to date, neither an effective antiviral drug nor a vaccine against SARS is available. However, it was found that a mixture of two HIV-1 proteinase inhibitors, lopinavir and ritonavir, exhibited some signs of effectiveness against the SARS virus. To understand the fine details of the molecular interactions between these proteinase inhibitors and the SARS virus via complexation, molecular dynamics simulations were carried out for the SARS-CoV 3CL(pro) free enzyme (free SARS) and its complexes with lopinavir (SARS–LPV) and ritonavir (SARS–RTV). The results show that flap closing was clearly observed when the inhibitors bind to the active site of SARS-CoV 3CL(pro). The binding affinities of LPV and RTV to SARS-CoV 3CL(pro) do not show any significant difference. In addition, six hydrogen bonds were detected in the SARS–LPV system, while seven hydrogen bonds were found in SARS–RTV complex.

    Search related documents:
    Co phrase search for related documents
    • active site and loop conformation: 1, 2, 3
    • active site and loop region: 1, 2, 3, 4, 5, 6
    • active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active site and lopinavir ritonavir drug: 1, 2
    • active site and low energy: 1, 2, 3, 4, 5, 6, 7, 8
    • active site and low flexibility: 1
    • active site and lpv complex: 1
    • active site and lpv inhibitor: 1, 2
    • active site bind and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • active site bind and lopinavir ritonavir: 1
    • active site bind and lopinavir ritonavir drug: 1
    • active site bind and low energy: 1, 2
    • acute respiratory syndrome and loop conformation: 1, 2, 3
    • acute respiratory syndrome and loop region: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir drug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and low energy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and low flexibility: 1, 2
    • acute respiratory syndrome and lpv inhibitor: 1, 2, 3, 4